Sovaldi, a new hepatitis C drug, has become an unbearable burden for medical insurance in the United States

Source: in a recent report commissioned by American payers on August 12, 2014, Milliman, who is in charge of actuarial business, predicted that in 2015, successful people with hepatitis C will increase federal spending by $2.9 billion to $5.8 billion In this way, the premium for the prescription drug program will rise by as much as 8.6% Mark? "This study shows that taxpayers will bear most of the increased costs for Medicare beneficiaries taking hepatitis C drugs," mark Merritt said in a statement The latest findings point to sovaldi and new hepatitis C drugs to be launched in the future In a recent review in the Journal of the American Medical Association (JAMA), two CVS executives predicted that the annual premium for each insured American could rise by $200 to $300 over the next five years Although the policyholder may bear part of the expenses, the payer is not happy at all about the expenses it has to bear Medicaid has asked for additional state funds to pay for sovaldi; Express scripts, a drug welfare management organization, has begun a series of programs to crowd out the drug But sovaldi's defenders have repeatedly stressed that there is a good reason for this surprising price tag In all patients, the cure rate of the drug is 95%, which can save the cost of further treatment, such as liver transplantation in some cases "Over time, these new drugs can transform the image of hepatitis C in the United States They can significantly eliminate the disease and reduce the deaths caused by the disease." "Compared with previous medical standards, using these new drugs to treat hepatitis C patients in the United States can save thousands of lives," wrote a new report from the California Institute of health care funded by the pharmaceutical industry